Biosimilars

Understanding biosimilars will be crucial for pharmacists as interchangeability comes into play.

Biosimilars for rituximab, trastuzumab, and bevacizumab are currently approved for use in the European Union.

Current developments and innovations that will shape the future of specialty pharmacy.

Ron Lanton III, Esq., President, True North Political Solutions, speaks about proposed legislation that could bolster the emergence of biosimilars.

In an effort to evaluate whether switching from a reference biologic to a biosimilar could lead to altered clinical outcome, a research team, led by Hillel Cohen, PhD, conducted a systematic literature review of all available switching studies.

The United States has been slow to embrace biosimilars, which may impact the overall effect they have on prescription drug spending.

The new purchasing efforts may help increase biosimilar uptake and lower drug costs.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Thirty-five percent of drug approvals in 2017 were personalized drugs.

With more biosimilars poised to enter the market, stakeholders seek to ensure safety and efficacy.

Ron Lanton III, Esq., President, True North Political Solutions, discusses the significant differences between biosimilars and generic drugs.

Top news of the week from Specialty Pharmacy Times.

Important considerations for pharmacists to concerning the switch from a brand name biologic to a new biosimilar.

Top news of the week from Specialty Pharmacy Times.

Biosimilars have yet to make a significant impact on the prescription drug market.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

The emergence of biosimilars will reduce spending on biologics by 3% through 2027.

Grant Knowles, PharmD, vice president, Business Development, Ardon Health, discusses the potential impact biosimilars will have in health care.

Top news of the week from Specialty Pharmacy Times.

Spending for adalimumab has tripled from 2012 from $4.5 billion.

Ron Lanton III, Esq, discusses all things biosimilar during a session at the National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference.

Pharmacists must be experts on follow-on biologics (FOBs), including biosimilars, so they can provide education to health professionals about safe prescribing and use, which ultimately affects patient care.

Biologics play a significant role in patient care, but because of the high cost of these medications, they may be inaccessible to patients and increase health care costs.

Draft guidance seeks to enhance equivalence testing for biosimilars.

The 15-page document offers guidance on statistical approaches to evaluating biosimilar similarity.

Sirukumab is an anti-interleukin-6 monoclonal antibody designed to block the IL-6 pathway in a different way than currently approved IL-6 inhibitors.

Results of the case could alter the future of the biosimilar marketplace.

Clinician and patient understanding and access considerations represent the most significant hurdles inhibiting the uptake of biosimilars for inflammatory conditions.